PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) CEO David Henry Mack Sells 58,411 Shares of Stock

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) CEO David Henry Mack sold 58,411 shares of the business’s stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $1.06, for a total value of $61,915.66. Following the sale, the chief executive officer directly owned 536,133 shares in the company, valued at $568,300.98. This trade represents a 9.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

PMV Pharmaceuticals Stock Performance

NASDAQ PMVP opened at $1.21 on Friday. The firm’s 50 day moving average price is $0.99 and its two-hundred day moving average price is $1.19. PMV Pharmaceuticals, Inc. has a twelve month low of $0.81 and a twelve month high of $1.82. The stock has a market cap of $62.86 million, a price-to-earnings ratio of -1.03 and a beta of 1.49.

PMV Pharmaceuticals (NASDAQ:PMVP) last issued its quarterly earnings results on Friday, May 9th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.03. On average, research analysts forecast that PMV Pharmaceuticals, Inc. will post -1.06 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective on shares of PMV Pharmaceuticals in a research note on Thursday, March 20th.

Hedge Funds Weigh In On PMV Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. BML Capital Management LLC boosted its holdings in shares of PMV Pharmaceuticals by 8.1% during the first quarter. BML Capital Management LLC now owns 3,747,612 shares of the company’s stock worth $4,085,000 after purchasing an additional 280,928 shares during the period. Stonepine Capital Management LLC increased its position in PMV Pharmaceuticals by 17.6% in the 1st quarter. Stonepine Capital Management LLC now owns 630,183 shares of the company’s stock worth $687,000 after purchasing an additional 94,378 shares during the last quarter. Aldebaran Capital LLC grew its stake in shares of PMV Pharmaceuticals by 4.3% in the 1st quarter. Aldebaran Capital LLC now owns 523,553 shares of the company’s stock valued at $571,000 after buying an additional 21,363 shares in the last quarter. Two Sigma Investments LP increased its holdings in PMV Pharmaceuticals by 5.0% in the fourth quarter. Two Sigma Investments LP now owns 506,986 shares of the company’s stock worth $766,000 after buying an additional 23,931 shares during the last quarter. Finally, Peapod Lane Capital LLC lifted its stake in PMV Pharmaceuticals by 9.8% in the first quarter. Peapod Lane Capital LLC now owns 489,370 shares of the company’s stock valued at $533,000 after acquiring an additional 43,626 shares during the last quarter. Hedge funds and other institutional investors own 90.20% of the company’s stock.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.